Adults experienced a significant reduction in HbA1c, Total Daily Dose & Hypoglycemic Events after only 3 months of Omnipod® use in a retrospective study of 3,592 patients⁵
CONTROL
HbA1c
• 2.3% reduction in HbA1c among adults with an HbA1c of >9% (n=1,745)
• 1.3% HbA1c reduction across all study participants
-2.3%
Total Daily Dose
• 35 U reduction in total daily insulin doses among prior MDI users (n=2,270)
• 32% reductionin TDD overall
-35 U
Hypoglycemic Events
Self-reported hypoglycemic events reduced by almost half from 1.2 down to 0.7 episodes/week
-42%
*Statistically significant with p value <0,0001
*
*
*
5
5,7
5,6
*Statistically significant with p value <0,0001
*Statistically significant with p value <0,0001
View Clinical Study
CLINICAL STUDY DESIGN
View Clinical Data
Aim of the study: to compare glycemic outcomes in adults with type 2 diabetes mellitus (T2DM) before and 90 days after initiating the Omnipod® System or the Omnipod DASH® Insulin Management Systems.
It was retrospective observational study (N = 3,592).
The primary outcome of this study was the change in HbA1c.
Secondary outcomes of this study included the change in TDD and self-reported frequency of HE (#/week <70 mg/dL).
•
•
•
•
5,7